Can less be more? new trial aims to cut harsh side effects in HPV throat cancer treatment
NCT ID NCT06702033
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study is for people with HPV-related throat cancer. After surgery, patients receive lower-than-standard doses of radiation and sometimes chemotherapy, based on their risk level. The goal is to keep cancer from coming back while reducing side effects like weight loss. About 142 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV-RELATED OROPHARYNX SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sanford Cancer Center
NOT_YET_RECRUITINGSioux Falls, South Dakota, 57104, United States
Contact Phone: •••-•••-••••
Contact
-
Sanford Roger Maris Cancer Center
NOT_YET_RECRUITINGFargo, North Dakota, 58102, United States
Contact Phone: •••-•••-••••
Contact
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cisplatin (chemotherapy) and radiation therapy (IMRT or IMPT)
What this could lead to
If successful, this could lead to a new standard of care that reduces harsh side effects from radiation and chemotherapy after surgery for HPV-related throat cancer.
What could go wrong
This is a Phase 2 trial with only 142 participants, so results are not definitive. Lowering treatment intensity might increase the risk of cancer recurrence.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.